ALK and neuroblastoma: Ceritinib, which received USA Food and Drug Administration approval in 2014 for treatment of patients with ALK-rearranged metastatic non-small cell lung cancer (NSCLC), has shown efficacy above that of Crizotinib in neuroblastoma models[37].